Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

Guidelines for point care testing: haematology.

BIBLIOGRAPHIC SOURCE(S)

  • Briggs C, Guthrie D, Hyde K, Mackie I, Parker N, Popek M, Porter N, General Haematology Task Force. Guidelines for point of care testing: haematology. London (UK): British Committee for Standards in Haematology; 2007 Jul 31. 29 p. [50 references]

GUIDELINE STATUS

This is the current release of the guideline.

It updates a previous version: Guide-lines for near patient testing: haematology. Near Patient Testing Working Party. General Haematology Task Force of BCSH. Thrombosis and Haemostasis Task Force of BCSH. Clin Lab Haematol. 1995 Dec;17(4):301-10.

The date for guideline review is 2009.

BRIEF SUMMARY CONTENT

 
RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

  1. The purpose, nature and potential benefits of point of care testing (POCT) at a particular site should be defined before initiating the service.
  2. A National Health Service (NHS) Trust POCT committee should be established and take responsibility for all POCT and ensure it is appropriate and accreditable. The committee should involve laboratory staff but also other relevant staff as appropriate. Where necessary there should also be a local point of care committee to oversee the service when it is in a non-hospital setting.
  3. The advice and involvement of an accredited clinical laboratory should be sought in order to achieve optimum quality and cost-effectiveness. This is also the recommendation for non-NHS sites (pharmacies for example). The haematology laboratory should play a key part in maintaining standards for patients in their catchment area.
  4. The POCT committee should be clear as to the purpose of the test: is it for diagnosis, screening for occult disease, monitoring disease or treatment?
  5. The POCT committee should investigate the full costs of the service including purchase costs and revenue costs including the cost of staff training.
  6. The POCT environment should be clean and well lit and may need temperature control. Service managers must perform a risk assessment of testing procedures. Equipment must be provided for the safe disposal of blood and contaminated consumables; staff must be trained in the use of this equipment.
  7. Documentation must include the name of the operator, date, patient identity details, results, lot number of calibrant, reagents and quality control materials. This must be recorded at the same time of analysis. A record of any maintenance and repairs and should also be kept. It is advisable to keep an 'error log' to assist any investigation of potential incidents.
  8. POCT raises the possibilities of litigation ensuing from erroneous results. Who bears legal responsibility locally should be established as well as the need for appropriate insurance coverage.
  9. All staff must recognise that only trained operators may use the equipment. An up-to-date list of trained operators and competency training should be maintained.
  10. POCT equipment should be uniform to allow simplification of training, storage and supply of reagents, servicing and maintenance.
  11. Internal quality control (IQC) and external quality assessment (EQA) programmes must be established.
  12. Since the problems arising from POCT are not inconsiderable, but can usually be overcome, the local haematologist and laboratory staff should be co-opted into the POCT service and involved in the ongoing provision of POCT.

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of supporting evidence is not specifically stated for each recommendation.

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

  • Briggs C, Guthrie D, Hyde K, Mackie I, Parker N, Popek M, Porter N, General Haematology Task Force. Guidelines for point of care testing: haematology. London (UK): British Committee for Standards in Haematology; 2007 Jul 31. 29 p. [50 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

1995 (revised 2007 Jul 31)

GUIDELINE DEVELOPER(S)

British Committee for Standards in Haematology - Professional Association

SOURCE(S) OF FUNDING

British Committee for Standards in Haematology

GUIDELINE COMMITTEE

British Committee for Standards in Haematology (BCSH) General Haematology Task Force

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Writing Group: Ms Carol Briggs, University College London Hospital, UK; Mr David Guthrie, Guy's & St Thomas' NHS Foundation Trust, London, UK; Dr Keith Hyde, Manchester Royal Infirmary, Manchester, UK; Dr Ian Mackie, University College London, UK; Dr Norman Parker, The Whittington Hospital, London, UK; Mrs Mary Popek, University College London Hospital, UK; Mr Neil Porter, The Royal Hallamshire Hospital, Sheffield

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

GUIDELINE STATUS

This is the current release of the guideline.

It updates a previous version: Guide-lines for near patient testing: haematology. Near Patient Testing Working Party. General Haematology Task Force of BCSH. Thrombosis and Haemostasis Task Force of BCSH. Clin Lab Haematol. 1995 Dec;17(4):301-10.

The date for guideline review is 2009.

GUIDELINE AVAILABILITY

Electronic copies: Available from the British Committee for Standards in Haematology Web site.

Print copies: Available from the British Committee for Standards in Haematology; Email: bcsh@b-s-h.org.uk.

AVAILABILITY OF COMPANION DOCUMENTS

None available

PATIENT RESOURCES

None available

NGC STATUS

This NGC summary was completed by ECRI Institute on March 18, 2008. The information was verified by the guideline developer on April 1, 2008.

COPYRIGHT STATEMENT

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo